×
About 1,155 results

ALLMedicine™ Paronychia Center

Research & Reviews  290 results

Spectrum of dermatologic adverse events associated with amivantamab use
https://www.mdedge.com/hematology-oncology/article/261095/melanoma/spectrum-dermatologic-adverse-events-associated
Walter Alexander

Feb 7th, 2023 - A case series of epidermal growth factor receptor (EGFR) exon 20 insertion–mutated advanced non–small cell lung cancer patients with dermatologic adverse events (dAEs) subsequent to treatment with amivantamab showed classic toxic effects associate.

Successful osimertinib rechallenge after severe thrombocytopenia caused by osimertinib ...
https://doi.org/10.1097/CAD.0000000000001443
Anti-cancer Drugs; Tan X, Chen S et. al.

Feb 3rd, 2023 - Osimertinib is recommended as the first-line treatment of advanced non-small cell lung cancer (NSCLC) in adults. The most commonly reported adverse events for osimertinib are skin effects, diarrhea, nausea, decreased appetite, fatigue, paronychia,...

Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and it...
https://doi.org/10.1007/s10637-023-01328-9
Investigational New Drugs; Ishikawa E, Yokoyama Y et. al.

Jan 14th, 2023 - Potential novel strategies for adverse event (AE) management of osimertinib therapy, including therapeutic drug monitoring and the use of biomarkers, have not yet been fully investigated. This study aimed to evaluate (1) the relationship between e...

Histopathological analysis of chronic paronychia.
https://doi.org/10.1111/ijd.16564
International Journal of Dermatology; Rocha BP, Verardino G et. al.

Jan 12th, 2023 - Chronic paronychia is an inflammatory process of the nail folds lasting more than 6 weeks. Clinically, there is hypertrophy and retraction of the folds and absence of the cuticle. Treatment involves clinical measures and, when there is no response...

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK in...
https://doi.org/10.1186/s12916-022-02669-7
BMC Medicine; Wang X, Luo Z et. al.

Jan 5th, 2023 - HL-085 is a selective, orally administered MEK1/2 inhibitor. We aimed to evaluate the safety and efficacy of HL-085 in patients with advanced melanoma harboring NRAS mutations. This was a multicenter phase 1 study. HL-085 was administered twice da...

see more →

Guidelines  1 results

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibito...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532717
Drugs Califano R, Tariq N et. al.

Jul 19th, 2015 - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a prove...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  12 results

Effect of Zanthoxylum Nitidum Tincture for Paronychia Caused by Afatinib
https://clinicaltrials.gov/ct2/show/NCT03908892

Aug 15th, 2022 - This is a randomized control trial evaluating the efficacy of zanthoxylum nitidum tincture on preventing progression of paronychia caused by afatinib from grade 1 to grade 2/3. Enrolled participates will randomly receive original treatment or orig...

The Efficacy of Topical Timolol Combined With Cryotherapy in EGFR Inhibitors-induced Paronychia - a Double-blinded, Intrapatient Left-to-right Controlled Study
https://clinicaltrials.gov/ct2/show/NCT05165082

Jun 8th, 2022 - Background: EGFR inhibitors (EGFRi) have been used to treat a wide variety of cancers nowadays. One of the major side effects of EGFRi is paronychia, which was not fatal but may caused huge negative impact on patient's daily activities. Current gu...

Panitumumab Skin Toxicity Prevention Trial
https://clinicaltrials.gov/ct2/show/NCT03167268

Sep 9th, 2021 - Background and rationale: EGFR represents the main and more studied signal activation pathway in the development of colorectal carcinoma. KRAS, NRAS, BRAF and PI3KA mutations and ERBB2 and MET amplification are responsible for most of the cases of...

StrataCTX® as a Steroid Sparing Device
https://clinicaltrials.gov/ct2/show/NCT04087629

Aug 9th, 2021 - Topical steroids are the mainstays of treatment for many cutaneous reactions and disorders. Steroids are known to cause many side effects and few effective pharmacologic alternatives exist. Contact dermatitis is observed in 56% of patients with cu...

Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitor...
https://clinicaltrials.gov/ct2/show/NCT03421912

Jul 9th, 2021 - The arrival of new therapeutic strategies such as targeted therapies has led to real progress in the treatment of cancers. Tyrosine kinase inhibitors and antibodies to epidermal growth factor receptors (EGFR), or iEGFR, target one of the major pat...

see more →

News  154 results

Spectrum of dermatologic adverse events associated with amivantamab use
https://www.mdedge.com/hematology-oncology/article/261095/melanoma/spectrum-dermatologic-adverse-events-associated
Walter Alexander

Feb 7th, 2023 - A case series of epidermal growth factor receptor (EGFR) exon 20 insertion–mutated advanced non–small cell lung cancer patients with dermatologic adverse events (dAEs) subsequent to treatment with amivantamab showed classic toxic effects associate.

Botanical Briefs: Daffodils (Narcissus Species)
https://www.mdedge.com/dermatology/article/260431/contact-dermatitis/botanical-briefs-daffodils-narcissus-species
Kevin P. Lee, MD, Dirk M. Elston, MD

Dec 30th, 2022 - Contact dermatitis is a common problem in the floral bulb industry and is considered an occupational disease. Daffodils (Narcissus species)(Figure) are thought to be the most common cause of irritant contact dermatitis among florists.

Epidermal Growth Factor Receptor Inhibitor–Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
https://www.mdedge.com/dermatology/article/260428/nonmelanoma-skin-cancer/epidermal-growth-factor-receptor-inhibitor
William Lewis, MD, Amy Forrestel, MD et. al.

Dec 30th, 2022 - Epidermal growth factor receptor (EGFR) inhibitors cause numerous cutaneous adverse events (AEs), including papulopustular eruptions, paronychia, acral fissures, xerosis, alopecia, and trichomegaly. 1 Symmetrical drug-related intertriginous and fle.

Dr. Piotrowska on the Management of Paronychia Associated With EGFR TKIs
https://www.onclive.com/view/dr-piotrowska-on-the-management-of-paronychia-associated-with-egfr-tkis

Nov 17th, 2022 - Zofia Piotrowska, MD, assistant professor of medicine, Harvard Medical School, assistant in medicine, Massachusetts General Hospital, discusses the management of paronychia associated with EGFR TKIs. Although paronychia is an adverse effect (AE) ...

Sunvozertinib Showcases Early Safety, Efficacy in EGFR Exon 20–Mutated NSCLC
https://www.onclive.com/view/sunvozertinib-showcases-early-safety-efficacy-in-egfr-exon-20-mutated-nsclc

Oct 30th, 2022 - Sunvozertinib (DZD9008) elicited promising responses as a second- or later-line treatment in patients with non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to D. Ross Camidge, MD, PhD, who added that further...

see more →

Patient Education  2 results see all →